These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma? Warner AB; Postow MA Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853 [TBL] [Abstract][Full Text] [Related]
7. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. Chang X; Lu X; Guo J; Teng GJ Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375 [TBL] [Abstract][Full Text] [Related]
8. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity? Wirsdörfer F; de Leve S; Jendrossek V Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587 [TBL] [Abstract][Full Text] [Related]
9. Emerging role of checkpoint inhibition in localized bladder cancer. Singh P; Black P Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977 [TBL] [Abstract][Full Text] [Related]
10. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy. Nadeau BA; Fecher LA; Owens SR; Razumilava N Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774 [TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720 [TBL] [Abstract][Full Text] [Related]
12. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. Sibaud V Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113 [TBL] [Abstract][Full Text] [Related]
13. Toxicities of checkpoint inhibitors: causes and management. Postow MA Clin Adv Hematol Oncol; 2019 Apr; 17(4):220-222. PubMed ID: 31188813 [No Abstract] [Full Text] [Related]
14. Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy. Bermudez MV; Papa S Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii1-vii6. PubMed ID: 31816083 [TBL] [Abstract][Full Text] [Related]
15. Toxicities associated with checkpoint inhibitors-an overview. Spiers L; Coupe N; Payne M Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085 [TBL] [Abstract][Full Text] [Related]
16. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives]. Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886 [TBL] [Abstract][Full Text] [Related]
17. State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours-a German radiation oncology survey. Käsmann L; Eze C; Dantes M; Roengvoraphoj O; Niyazi M; Belka C; Manapov F Eur J Cancer; 2019 Feb; 108():50-54. PubMed ID: 30648629 [TBL] [Abstract][Full Text] [Related]
18. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview. Plachouri KM; Vryzaki E; Georgiou S Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498 [TBL] [Abstract][Full Text] [Related]
19. [Synergy between radiotherapy and immunotherapy in the treatment of advanced malignancies: recent evidences of a new challenge in oncology]. Corvò R; Belgioia L Recenti Prog Med; 2015 Jul; 106(7):322-30. PubMed ID: 26228723 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review. Trapani S; Manicone M; Sikokis A; D'Abbiero N; Salaroli F; Ceccon G; Buti S Crit Rev Oncol Hematol; 2019 Oct; 142():9-15. PubMed ID: 31325712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]